2026 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
Across Asia, regulators are rethinking how innovation reaches patients—whether by speeding reviews, overhauling frameworks, or piloting new approval pathways. These shifts highlight policy as a powerful lever shaping the future of drug development.
The proportion of China-originated drugs granted expedited reviews in China doubled in the first half of this year, Pharmaprojects data show, surpassing those receiving similar treatment in the US and likely driven by multiple factors.
India is pressing ahead with “big shifts” in its regulatory approach for cell and gene therapies. Reduced “layers of review”, tighter internal timelines, upcoming guidelines to facilitate CGT development and reforms in the constitution of expert committees are some of the key changes.
In an ongoing effort to accelerate the commercialization of select innovative drugs and medical devices, Korea’s MFDS is launching a new program for certain products that will receive regular regulatory consultations until they reach the approval stage.
